Skyline Diagnostics
SkylineDx, NeraCare Partnering on Proteomic Test for Melanoma
The companies inked a codevelopment and licensing agreement for NeraCare's Immunoprint test for identifying high-risk early-stage melanoma patients.
SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay
The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.
SkylineDx, VIB Form Molecular Diagnostics Partnership
The partnership will focus on high-potential in vitro diagnostic opportunities for unmet medical needs for global markets.
Biocartis, SkylineDx Partner to Develop Melanoma Nodal Metastasis Risk Test
The Belgian molecular diagnostics firm also reported a 70 percent year-over-year increase in commercial cartridge volumes in the first quarter.
SkylineDx, Imperial College London, UCSD Partner to Develop Kawasaki Disease Test
The test is based on 13 genes that form a gene signature in the blood of children with Kawasaki disease, and it enables KD to be distinguished from other diseases.